Literature DB >> 19900402

Concurrent targeting of nitrosative stress-PARP pathway corrects functional, behavioral and biochemical deficits in experimental diabetic neuropathy.

Geeta Negi1, Ashutosh Kumar, Shyam S Sharma.   

Abstract

Peroxynitrite mediated nitrosative stress, an indisputable initiator of DNA damage and overactivation of poly(ADP-ribose) polymerase (PARP), a nuclear enzyme activated after sensing DNA damage, are two crucial pathogenetic mechanisms in diabetic neuropathy. The intent of the present study was to investigate the effect of combination of a peroxynitrite decomposition catalyst (PDC), FeTMPyP and a PARP inhibitor, 4-ANI against diabetic peripheral neuropathy. The end points of evaluation of the study included motor nerve conduction velocity (MNCV) and nerve blood flow (NBF) for evaluating nerve functions; thermal hyperalgesia and mechanical allodynia for assessing nociceptive alterations, malondialdehyde and peroxynitrite levels to detect oxidative stress-nitrosative stress; NAD concentration in sciatic nerve to assess overactivation of PARP. Additionally immunohistochemical studies for nitrotyrosine and Poly(ADP-ribose) (PAR) was also performed. Treatment with the combination of FeTMPyP and 4-ANI led to significant improvement in nerve functions and pain parameters and also attenuated the oxidative-nitrosative stress markers. Further, the combination also reduced the overactivation of PARP as evident from increased NAD levels and decreased PAR immunopositivity in sciatic nerve microsections. Thus, it can be concluded that treatment with the combination of a PDC and PARP inhibitor attenuates alteration in peripheral nerves in diabetic neuropathy (DN). Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19900402     DOI: 10.1016/j.bbrc.2009.11.010

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

Review 1.  Diabetic peripheral neuropathy: should a chaperone accompany our therapeutic approach?

Authors:  Kevin L Farmer; Chengyuan Li; Rick T Dobrowsky
Journal:  Pharmacol Rev       Date:  2012-08-10       Impact factor: 25.468

2.  Role of melatonin on diabetes-related metabolic disorders.

Authors:  Javier Espino; José A Pariente; Ana B Rodríguez
Journal:  World J Diabetes       Date:  2011-06-15

3.  Possible involvement of nitric oxide modulatory mechanism in the protective effect of retigabine against spinal nerve ligation-induced neuropathic pain.

Authors:  Raghavender Pottabathini; Anil Kumar; Archana Bhatnagar; Sukant Garg
Journal:  Cell Mol Neurobiol       Date:  2014-09-03       Impact factor: 5.046

Review 4.  Diabetic neuropathy: cellular mechanisms as therapeutic targets.

Authors:  Andrea M Vincent; Brian C Callaghan; Andrea L Smith; Eva L Feldman
Journal:  Nat Rev Neurol       Date:  2011-09-13       Impact factor: 42.937

Review 5.  Peroxynitrite-driven mechanisms in diabetes and insulin resistance - the latest advances.

Authors:  K Stadler
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

6.  MEK inhibition suppresses the development of lung fibrosis in the bleomycin model.

Authors:  Maria Galuppo; Emanuela Esposito; Emanuela Mazzon; Rosanna Di Paola; Irene Paterniti; Daniela Impellizzeri; Salvatore Cuzzocrea
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-02       Impact factor: 3.000

Review 7.  The emerging role of autophagy in the pathophysiology of diabetes mellitus.

Authors:  Claudio D Gonzalez; Myung-Shik Lee; Piero Marchetti; Massimo Pietropaolo; Roberto Towns; Maria I Vaccaro; Hirotaka Watada; John W Wiley
Journal:  Autophagy       Date:  2011-01-01       Impact factor: 16.016

8.  Histamine H4 receptor agonist-induced relief from painful peripheral neuropathy is mediated by inhibition of spinal neuroinflammation and oxidative stress.

Authors:  Maria Domenica Sanna; Laura Lucarini; Mariaconcetta Durante; Carla Ghelardini; Emanuela Masini; Nicoletta Galeotti
Journal:  Br J Pharmacol       Date:  2016-11-18       Impact factor: 8.739

Review 9.  SOD therapeutics: latest insights into their structure-activity relationships and impact on the cellular redox-based signaling pathways.

Authors:  Ines Batinic-Haberle; Artak Tovmasyan; Emily R H Roberts; Zeljko Vujaskovic; Kam W Leong; Ivan Spasojevic
Journal:  Antioxid Redox Signal       Date:  2013-10-01       Impact factor: 8.401

10.  Inhibition of IκB kinase (IKK) protects against peripheral nerve dysfunction of experimental diabetes.

Authors:  Geeta Negi; Shyam S Sharma
Journal:  Mol Neurobiol       Date:  2014-06-20       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.